REGENXBIO Inc. (RGNX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $29.26M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$83.36M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$52.41M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$63.28M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $29.26M | (m) | $108.02M | (m) | $760.00K* | -$62.24M* | (m) | $56.09M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$83.36M | (m) | $6.39M | (m) | $1.24M | -$76.19M | (m) | $57.34M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$52.41M | (m) | $29.73M | (m) | $491.00K* | -$55.96M* | (m) | $56.10M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$63.28M | (m) | $21.36M | (m) | $391.00K* | -$49.34M* | (m) | $59.50M | (m) | (m) |
| 2025-03-31 | Reported | (m) | $12.13M | (m) | $89.01M | (m) | $1.02M | $33.63M | (m) | $53.09M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$62.08M | (m) | $24.20M | (m) | $326.00K* | -$40.55M* | $12.39M | $54.43M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$56.04M | (m) | $22.30M | (m) | $474.00K* | -$45.50M* | $10.58M | $48.87M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$63.86M | (m) | $15.62M | (m) | $557.00K | -$55.45M | $4.28M | $54.84M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$64.96M | (m) | $28.91M | (m) | $1.44M* | -$49.41M* | $12.39M | $58.18M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$73.11M | (m) | $19.98M | (m) | $2.58M* | -$47.32M* | $9.47M | $59.89M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$66.16M | (m) | $19.14M | (m) | $4.82M | -$80.92M | $4.11M | $58.52M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$71.05M | (m) | $26.51M | (m) | $5.05M* | -$50.46M* | $13.09M | $63.31M | (m) | $0.00* |
| 2022-06-30 | Reported | (m) | -$62.53M | (m) | $32.65M | (m) | $9.24M* | -$61.75M* | $12.95M | $61.01M | (m) | $0.00* |
| 2022-03-31 | Reported | (m) | -$71.53M | (m) | $22.22M | (m) | $10.97M | -$55.91M | $15.72M | $55.63M | (m) | -$41.00K |
| 2021-09-30 | Reported | (m) | -$57.35M | (m) | $30.77M | (m) | $18.70M* | -$42.50M* | $14.11M | $47.85M | (m) | $0.00* |
| 2021-06-30 | Reported | (m) | -$52.23M | (m) | $22.04M | (m) | $19.84M* | -$36.07M* | $9.82M | $45.88M | (m) | $0.00* |
| 2021-03-31 | Reported | (m) | -$44.04M | (m) | $18.88M | (m) | $31.02M | -$44.05M | $4.85M | $39.72M | (m) | $4.00K |
| 2020-09-30 | Reported | (m) | $13.95M | (m) | $98.91M | (m) | $6.07M* | -$36.46M* | $17.36M | $43.97M | (m) | -$3.00K |
| 2020-06-30 | Reported | (m) | -$41.83M | (m) | $16.57M | (m) | $3.28M* | -$21.50M* | $4.68M | $38.11M | (m) | -$500.00K |
| 2020-03-31 | Reported | (m) | -$37.70M | (m) | $17.64M | (m) | $4.63M | -$35.57M | $3.41M | $37.03M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$35.90M | (m) | $14.70M | (m) | $2.68M* | -$29.15M* | $2.49M | $35.69M | (m) | -$165.00K |
| 2019-06-30 | Reported | (m) | -$36.87M | (m) | $7.88M | (m) | $5.55M* | -$23.75M* | $1.93M | $29.48M | (m) | -$129.00K |
| 2019-03-31 | Reported | (m) | -$35.91M | (m) | $884.00K | (m) | $2.46M | -$29.30M | $29.00K | $25.20M | (m) | $70.00K |
| 2018-09-30 | Reported | (m) | -$22.73M | (m) | $5.31M | (m) | $3.37M* | -$19.56M* | $517.00K | $18.51M | (m) | -$1.29M |
| 2018-06-30 | Reported | (m) | $6.35M | (m) | $40.03M | (m) | $2.67M* | $70.21M* | $3.87M | $21.49M | (m) | $3.85M |
| 2018-03-31 | Reported | (m) | $102.03M | (m) | $132.39M | (m) | $2.34M | $58.13M | $2.41M | $19.55M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$21.31M | (m) | $1.34M | (m) | $450.00K* | -$17.14M* | (m) | $12.52M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$15.06M | (m) | $6.56M | (m) | $1.68M* | (m) | (m) | $13.92M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$22.92M | (m) | $455.00K | (m) | $2.93M | (m) | (m) | $16.62M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$18.67M | (m) | (m) | (m) | $2.22M* | (m) | (m) | $12.56M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$14.95M | (m) | (m) | (m) | $1.07M* | (m) | (m) | $10.68M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$11.25M | (m) | (m) | (m) | $416.00K | (m) | (m) | $6.18M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$7.35M | (m) | (m) | (m) | $79.00K* | (m) | (m) | $5.66M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$6.30M | (m) | (m) | (m) | $209.00K* | (m) | (m) | $4.01M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$3.99M | (m) | (m) | (m) | $106.00K | (m) | (m) | $2.79M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$1.70M | (m) | (m) | (m) | (m) | (m) | (m) | $1.08M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$161.20M | (m) | $170.44M | (m) | $2.41M | -$123.96M | (m) | $228.30M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$233.35M | (m) | $83.33M | (m) | $2.44M | -$173.13M | $33.57M | $208.52M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$268.13M | (m) | $90.24M | (m) | $9.96M | -$218.41M | $37.21M | $232.27M | (m) | -$152.00K |
| 2022-12-31 | Reported | (m) | -$262.88M | (m) | $112.72M | (m) | $30.72M | -$207.49M | $54.55M | $242.45M | (m) | -$84.00K |
| 2021-12-31 | Reported | (m) | $159.98M | (m) | $470.35M | (m) | $84.17M | $218.88M | $51.83M | $181.44M | (m) | $13.41M |
| 2020-12-31 | Reported | (m) | -$119.23M | (m) | $154.57M | (m) | $26.87M | -$54.06M | $35.71M | $166.29M | (m) | $5.24M |
| 2019-12-31 | Reported | (m) | -$149.00M | (m) | $35.23M | (m) | $11.72M | -$107.70M | $8.24M | $124.19M | (m) | -$2.75M |
| 2018-12-31 | Reported | (m) | $88.10M | (m) | $218.50M | (m) | $13.28M | $104.65M | $9.64M | $83.87M | (m) | $4.18M |
| 2017-12-31 | Reported | (m) | -$75.89M | (m) | $10.39M | (m) | $7.16M | -$57.99M | $1.71M | $57.22M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$65.34M | (m) | $4.59M | (m) | $8.15M | -$48.56M | (m) | $45.48M | (m) | -$435.00K |
| 2015-12-31 | Reported | (m) | -$23.14M | (m) | (m) | (m) | $522.00K | (m) | (m) | $17.28M | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$3.68M | (m) | (m) | (m) | (m) | (m) | (m) | $4.96M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$4.78M | (m) | (m) | (m) | (m) | (m) | (m) | $5.05M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |